BioSpace News Archive

On Friday, January 27, 2023, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), filed its financial results for the fiscal year ended February 28, 2022.

Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.

Tyber Medical LLC has acquired 100 percent of the capital of ADSM-Synchro Medical, a French orthopedic medical device company, specializing in the development and distribution of implants dedicated to treating surgical forefoot pathologies.

PetDx® – The Liquid Biopsy Company for Pets™ published a study describing the optimal age to begin cancer screening for dogs in PLOS ONE, a peer-reviewed open-access scientific journal from the Public Library of Science.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

MDxHealth SA, a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares in a registered public offering.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023.

Cytokinetics, Incorporated announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment.

Paratek Pharmaceuticals, Inc. announced that on January 31, 2023, the Company granted stock options to four new employees of the Company.

Vera Therapeutics, Inc. announced that it has commenced a public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its Class A common stock.